Thông tư 01/2018/TT-BYT về ghi nhãn thuốc, tờ hướng dẫn sử dụng thuốc

THE MINISTRY OF HEALTH

Circular No. 01/2018/TT-BYT dated January18, 2018 of the Ministry of Health onlabeling and package inserts of drugs and medicinal ingredients

Pursuant to the Law on Pharmacy No. 105/2016/QH13 dated April 06, 2016;

Pursuant to the Government’s Decree No. 54/2017/ND-CP dated May 08, 2017 on guidelines for implementation of the Law on Pharmacy;

Pursuant to the Government’s Decree No. 43/2017/ND-CP dated April 14, 2017 on good labeling;

Pursuant to the Government’s Decree No. 75/2017/ND-CP dated June 20, 2017 defining Functions, Tasks, Powers and Organizational Structure of Ministry of Health;

At the request of the Director of the Drug Administration of Vietnam;

Minister of Health promulgates a Circular on labeling of drugs, medicinal ingredients and package inserts.

Chapter I

GENERAL PROVISIONS

Article 1. Scopeof adjustment

1. This Circular provides for information on labels, methods for labeling and package inserts of drugs and medicinal ingredients sold on the market; change of expiry dates of labeled drugs because of national defense and security, epidemic control or disaster recovery need.

2. This Circular does not apply to labels of:

a) Drugs and medicinal ingredients which are used for export but not yet registered in Vietnam;

b) Drugs imported for non-commercial purposes as regulated in Clause 1 Article 75 of the Government’s Decree No. 54/2017/ND-CP dated May 08, 2017 on guidelines for implementation of the Law on Pharmacy (hereinafter referred to as “Decree No. 54/2017/ND-CP”);

c) Drugs imported to meet urgent need of national defense and security, epidemic control or disaster recovery as regulated in Clause 1 Article 67 of the Decree No. 54/2017/ND-CP.

Article 2. Interpretation of terms

For the purpose of this Circular, the terms below are construed as follows:

1.“commercial package of a drug” means the package that envelops the drugs and the package insert and is sold together with drugs. Commercial packages of drugs include primary package, secondary package, and probably intermediate package.

2.“intermediate package” means the package which is used to wrap one or some units of drugs that already have primary packages and contained in the secondary package.

3.“batch number” means a series of numbers or letters or both that helps recognize the batch of drug or medicinal ingredient and permits the trace of history of a batch of drugs or medicinal ingredients, including all production stages, quality inspections and sale of that batch of drugs or medicinal ingredients.

4.“original label” means the label that is first affixed by the manufacturer on the commercial packages of the drug or medicinal ingredient.

Article 3. Positions of labels of drugs or medicinal ingredients and package inserts

1. Positions of labels of drugs or medicinal ingredients shall follow regulations in Article 4 of the Government’s Decree No. 43/2017/ND-CP dated April 14, 2017 on good labeling (hereinafter referred to as “Decree No. 43/2017/ND-CP”).

2. Package insert is an integral part of the drug label and contained in the secondary package. If a drug does not have the secondary package, the package insert must be printed or affixed on the primary package.

Article 4. Sizes of labels, sizes of letters and numbers on labels, colors of text, symbols, and pictures on the labels, languages on labels and package inserts

1. Sizes of labels, sizes of letters and numbers on labels, colors of text, symbols, and pictures on the labels of drugs or medicinal ingredients and package inserts shall follow regulations in Article 5 (excluding regulations in Point b Clause 2 Article 5) and Article 6 of the Decree No. 43/2017/ND-CP.

2. Compulsory information on a label of drug or medicinal ingredient and the package insert must be written in Vietnamese language, except for some contents which may be written in other Romance languages as regulated in Clause 4 Article 7 of the Decree No. 43/2017/ND-CP.

Article 5. Affixing secondary labels and addition or replacement of package inserts in Vietnam

1. If the original label of drugs or medicinal ingredients imported into Vietnam does not contain sufficient compulsory information as regulated by the Ministry of Health, the importer must keep the original label unchanged and affix the secondary labels in Vietnamese language in conformity with regulations of the Ministry of Health before such imported drugs or medicinal ingredients are sold on the market.

2. Importers in the following cases shall be granted customs clearance in order to add or replace package inserts in Vietnamese language in Vietnam:

a) Imported drugs which have been granted the Certificate of registration in Vietnam and have the package inserts in Vietnamese language contained in their commercial packages but been not yet updated with compulsory information as regulated the Ministry of Health, except for the cases where package inserts are exempted according to regulations in Points a, b, c and d Clause 1 Article 13 herein;

b) Imported drugs which are not yet granted the Certificate of registration in Vietnam and do not have the package inserts in Vietnamese language contained in their commercial packages, except for the cases where package inserts are exempted according to regulations in Points a, b, c, d and dd Clause 1 Article 13 herein.

3. Principles and locations for affixing secondary labels and adding or replacing package inserts in Vietnam:

After the customs clearance is granted, importers of drugs or medicinal ingredients mentioned in Clause 1 and Clause 2 of this Article must affix the secondary labels, add or replace package inserts in Vietnamese language according to the following principles:

a) Secondary labels shall be affixed in a drug or medicinal ingredient storage facility that has GSP certificate of the importer;

b) Package inserts in Vietnamese language shall be added or replaced by the secondary packaging division of a facility that has GMP certificate in conformity with the scope of the Certificate of eligibility for pharmacy business;

c) Affixing secondary labels or adding or replacing package inserts in Vietnamese language in Vietnam should avoid influencing the quality of drugs or medicinal ingredients.

4. In case of addition or replacement of package inserts in Vietnamese language as regulated in Point b Clause 3 of this Article, the secondary packaging facility must properly comply with GMP guidelines in course of adding or replacing package inserts as regulated in Point b Clause 3 of this Article and also submit reports to the Ministry of Health to serve the fulfillment of pharmacy business management and inspection tasks. To be specific:

a) Reports must be submitted within one (01) month from the completion of the addition or replacement of package inserts in Vietnam;

b) A report must contain the following compulsory contents: Name of importer; name of drug; registration number or import license number; batch number; manufacturing date; expiry date; quantity of drugs of which package inserts have been added or replaced.

5. The entity responsible for labeling shall supervise and cooperate with the facility in charge of affixing secondary labels or adding or replacing package inserts and assume responsibility for quality of drugs or medicinal ingredients during the affixing of secondary labels or addition or replacement of package inserts.

Article 6. Responsibility for labeling of drugs and medicinal ingredients and package inserts

1. Entities responsible for labeling of drugs or medicinal ingredients, including secondary labels and package inserts, must ensure that the information on labels must be truthful, clear and accurate, and reflect the nature of drugs or medicinal ingredients.

2. With regard to drugs or medicinal ingredients manufactured in Vietnam:

a) The manufacturer and/or registrant are responsible for labeling and package inserts of drugs or medicinal ingredients manufactured and/or registered;

b) Health facilities that are allowed to prepare traditional drugs in accordance with regulations in Clause 1 and Clause 2 Article 70 of the Law on Pharmacy and health facilities that are allowed to produce and prepare drugs in accordance with regulations in Clause 2 and Clause 3 Article 85 of the Law on Pharmacy are responsible for labeling of their drugs prepared or produced;

c) Drugstores that prepare prescription drugs and sell them in accordance with regulations in Point b Clause 1 Article 47 of the Law on Pharmacy are responsible for labeling of their prescription drugs prepared.

3. With regard to imported drugs or medicinal ingredients:

a) The importer and/or registrant of drugs are responsible for labeling and package inserts of drugs having registration numbers;

b) The importer and/or registrant of medicinal ingredients are responsible for labeling of imported medicinal ingredients;

c) The importer is responsible for labeling and package inserts of imported drugs without registration numbers.

4. With regard to medicinal ingredients divided into smaller package units in course of wholesale or retail: Pharmacy business establishments that divide drugs into smaller package units are responsible for affixing secondary labels in conformity with regulations in Clause 2 and Clause 3 Article 7 herein.

Chapter II

INFORMATION ON DRUG LABELS AND PACKAGE INSERTS

Section 1. COMPULSORY INFORMATION ON LABELS

Article 7. Secondary package labels of drugs and medicinal ingredients

1. The secondary package label of drugs must contain the compulsory information below:

a) The drug name;

b) Dosage form;

c) The composition of the drugs, contents, weights or concentrations of active ingredients or herbal ingredients;

d) Package contents;

dd) Indications, usage instructions and contraindications;

e) Registration number or import license number (if any);

g) Batch number, manufacturing date, expiry date, quality standards and storage conditions;

h) Precautions and recommendations;

i) Name and address of manufacturer;

k) Name and address of importer (for imported drugs);

l) Drug origin.

2. The secondary package label of medicinal ingredients (including herbal ingredients, traditional ingredients, semi-finished drugs and semi-finished herbal medicines) must contain the compulsory information below:

a) Name of medicinal ingredients;

b) Weight or volume of medicinal ingredients contained in a smallest package unit;

c) Quality standards of medicinal ingredients;

d) Registration number or import license number (if any);

dd) Batch number, manufacturing date, expiry date and storage conditions;

e) Name and address of manufacturer of medicinal ingredients;

g) Name and address of importer (for imported medicinal ingredients);

h) Origin of medicinal ingredients.

3. Labels of controlled medicinal ingredients (including controlled semi-finished drugs):

In addition to compulsory information specified in Clause 2 of this Article, the following texts must be specified on secondary labels of medicinal ingredients which are active ingredients, herbal ingredients or semi-finished drugs containing active ingredients or herbal ingredients on the Lists of narcotic active ingredients, psychotropic ingredients, drug precursors, toxic medicinal ingredients, toxic herbal ingredients and radioactive medicinal ingredients: “Narcotic active ingredients”, “Psychotropic ingredients”, “Drug precursors", “Toxic medicinal ingredients”, “Toxic herbal ingredients” or “Radioactive medicinal ingredients”.

The text : “Narcotic active ingredients”, “Psychotropic ingredients”, “Drug precursors", “Toxic medicinal ingredients”, “Toxic herbal ingredients” or “Radioactive medicinal ingredients” must be printed bold type in box and on the main side of the label on which the name of medicinal ingredients is specified.

4. If the secondary package label cannot contain all compulsory information prescribed in Clause 1 of this Article, the information specified in Point dd Clause 1 of this Article may be briefly summarized by the following text: “Please refer to the package insert for indications, usage instructions, contraindications and other information”.

Article 8. Intermediate package labels

1. The intermediate package label of drugs must contain the compulsory information below:

a) The drug name;

b) Batch number;

c) Expiry date.

2. If the intermediate package is made of transparent materials through which information on the primary package label may be revealed, it is not required to have the information specified in Clause 1 of this Article.

Article 9. Primary package labels of drugs and medicinal ingredients

1. The primary package label of drugs must contain the compulsory information below:

a) The drug name;

b) The composition of the drugs, contents, weights or concentrations of active ingredients or herbal ingredients;

c) Batch number;

d) Expiry date;

dd) Name of manufacturer.

2. Primary package labels of medicinal ingredients:

If the secondary package label of medicinal ingredients contains sufficient compulsory information as regulated in Clause 2 and Clause 3 Article 7 herein, the primary package label may be exempted provided that the medicinal ingredients are not divided for retail.

3. If there is no secondary package, primary package labels of drugs and medicinal ingredients must contain sufficient information of secondary package labels as regulated in Article 7 herein.

Article 10. Secondary labels

1. The secondary label shall contain every compulsory information which is not written on the original label in Vietnamese language as prescribed in Article 7 of this Circular.

2. If the secondary label is so small that it cannot contain compulsory information as specified in Clause 1 of this Article 7, certain compulsory information may be written as follows:

a) Indications, usage instructions, contraindications and other information: Please refer to the package insert;

b) The way to find out the information about manufacturing date, expiry date and batch number printed on the original label must be available;

c) Registration number or import license number may not be specified but the information about registration number or import license number (if any) must be specified before drugs are sold on the market.

Article 11. Drug labels in other cases

1. Traditional drugs prepared according to regulations in Clause 1 and Clause 2 Article 70 of the Law on Pharmacy and drugs produced and prepared according to regulations in Clause 2 and Clause 3 Article 85 of the Law on Pharmacy must have labels containing the following compulsory information, except for the cases mentioned in Clause 3 of this Article:

a) The secondary package label of traditional drugs and prepared drugs must contain the following information:

- The information prescribed in Points a, b, c, d, dd, g and h Clause 1 Article 7 herein;

- Name and address of health facility producing or preparing drugs.

b) The primary package label of traditional drugs must contain the compulsory information below:

- The information prescribed in Points a, b, c and d Clause 1 Article 9 herein;

- Name of health facility producing or preparing drugs.

c) If there is no secondary package, the primary package label of traditional drugs and prepared drugs must contain sufficient compulsory information of the secondary package label as prescribed in Point a Clause 1 of this Article.

2. Drugs prepared according to prescriptions and sold at drugstores in accordance with regulations in Point b Clause 1 Article 47 of the Law on Pharmacy must have secondary package labels or primary package labels containing the compulsory information below:

a) Drug name, dosage form;

b) Active ingredients and concentrations or contents thereof;

c) Preparation date, expiry date, storage conditions;

d) Name and address of drugstore preparing drugs;

dd) Name of patient presenting the prescription;

e) Precautions for controlled drugs.

3. Traditional drugs prepared according to prescriptions in accordance with regulations in Clause 1 Article 70 of the Law on Pharmacy are exempted from labeling as prescribed in this Circular but must have the secondary package on which full name and age of patient are specified to avoid mistake while delivering drugs.

4. Drugs which have been not yet granted the Certificate of registration in Vietnam but are imported to serve the purpose of bioequivalence study, bioavailability assessment, use as specimens for registration, testing or scientific research, or display at a fair or exhibition shall be exempted from labeling with compulsory information prescribed in Article 7 and Article 8 herein but must have their original labels unchanged and affixed with secondary labels as follows:

a) The secondary label of drugs used for bioequivalence study, bioavailability assessment or as specimens for testing or scientific research must have the text “Drugs used for research purpose”;

b) The secondary label of drugs used as specimens for registration must have the text “Drugs used as registration specimens”;

c) The secondary label of drugs used for display at a fair or exhibition must have the text “Drugs for display”.

5. Medicinal ingredients which are active ingredients and have been not yet granted the Certificate of registration in Vietnam but are imported to use as specimens for registration, testing or research, or for display at a fair or exhibition in accordance with regulations in Clause 3 Article 60 of the Law on Pharmacy shall be exempted from labeling with compulsory information prescribed in Article 7 and Article 8 herein but must have their original labels unchanged.

6. Medicinal ingredients which are active ingredients, recipients or semi-finished drugs and have been not yet granted the Certificate of registration in Vietnam but are imported to produce drugs according to registration documents of drugs granted the Certificate of registration in Vietnam must have secondary labels containing compulsory information prescribed in Clause 2 and Clause 3 Article 7 herein (except for name and address of importer). The secondary label may be exempted if the original label contains all this compulsory information in other Romance languages.

7. Drugs imported in accordance with regulations in Point b Clause 1 Article 68 of the Decree No. 54/2017/ND-CP shall be exempted from labeling in Vietnamese language as regulated herein provided that their original labels must be kept unchanged.

Section 2. INFORMATION ON PACKAGE INSERTS

Article 12. Information on package inserts

The package insert of drugs must contain the compulsory information below:

1. The drug name.

2. Precautions and recommendations.

3. Composition of the drug.

4. Dosage form.

5. Indications.

6. Usage instructions and dose.

7. Contraindications.

8. Warnings and cautions.

9. Warnings for the use of drugs during pregnancy and breastfeeding.

10. Influence of the drug on ability to drive or operate machinery.

11. Drug interactions and incompatibilities.

12. Adverse drug reactions.

13. Overdose and treatment.

14. Information about pharmacodynamics (not applicable to OTC drugs, herbal drugs and traditional drugs).

15. Information about pharmacokinetics (not applicable to OTC drugs, herbal drugs and traditional drugs).

16. Package contents.

17. Storage conditions, expiry date and quality standards.

18. Name and address of manufacturer.

Article 13. Requirements of a package insert

1. Every drug sold on the market, or produced or prepared by a health facility as regulated in Clause 1 Article 11 herein, must have a package insert written in Vietnamese language, except for the following cases:

a) Drugs produced or prepared according to traditional remedies or prescriptions as regulated in Clause 1 Article 70 and Clause 2 Article 85 of the Law on Pharmacy for use or retail according to prescriptions at health facilities;

b) Drugs prepared and retailed at drugstores in accordance with regulations in Point b Clause 1 Article 47 of the Law on Pharmacy;

c) Drugs which have been not yet granted the Certificate of registration in Vietnam but are imported to serve the purpose of bioequivalence study, bioavailability assessment, use as specimens for registration, testing or scientific research, or display at a fair or exhibition;
d) Drugs imported in accordance with regulations in Point b Clause 1 Article 68 of the Decree No. 54/2017/ND-CP;

dd) OTC drugs having labels containing all compulsory information of the package insert as prescribed in Article 12 herein.

2. Package inserts in foreign languages of the drugs mentioned in Point d Clause 1 of this Article must be kept unchanged.

3. If multiple drugs share the same name, active ingredients, herbal ingredients, dosage form, administration route, indications and manufacturer but the volume, contents, concentrations, weights or package contents are different and all of them are permitted for free sale, they may be written on the same package insert.

If there are differences in concentrations or contents, it is required to specify the concentrations, contents, volumes or package contents.
4. At least one package insert in Vietnamese language must be contained in the secondary package of drugs. If there is no secondary package, at least one package insert must be contained in the primary package of drugs.

Chapter III

PRESENTATION OF INFORMATION ON DRUG LABELS AND PACKAGE INSERTS

Article 14. Names of drugs and medicinal ingredients

1. The name of drug or medicinal ingredient must be easily recognizable and of a size bigger than that of other compulsory information on the label or package insert.

2. The name of drug or medicinal ingredient must be written in a Romance language and may contain digits, Roman numbers or other symbols written in Greek alphabet (e.g. alpha, beta).

3. The drug name shall be its trade name or international nonproprietary name. Names of traditional drugs on the List of traditional drugs recognized by the Ministry of Health shall be trade names or names of traditional remedies approved by the Ministry of Health, except traditional ingredients. The trade name of drug should not:

a) Provide any advertising information;

b) Provide any misleading information about the composition or origin of the drug. If the drug contains multiple active ingredients or herbal ingredients, the name of any ingredient is not used as the drug name;

c) Cause misinterpretation or provide exaggerated description of effects or indications of the drug;

d) Show any disrespect to Vietnamese traditional values and customs;

dd) Cause conflicts with protected products of other intellectual property rights holders;

e) Be identical or similar to the name of drugs granted certificate of registration of another facility;

g) Use the same name for drugs containing different active ingredients;

h) Use different names for the drugs that have same active ingredients or herbal ingredients, dosage form, administration route, concentrations or contents and manufacturer. This provision shall not apply to processed drugs which shall be governed by specific regulations on domestic processing of drugs announced by the Minister of Health;

i) If multiple drugs share the same name, manufacturer, dosage form and active ingredients but the concentrations or contents are different, corresponding concentrations or contents may be written next to the drug name in a recognizable way.

4. The name of medicinal ingredients (excluding herbal ingredients and semi-finished drugs) shall be written in accordance with regulations in Clause 2 Article 16 herein.

5. The name of traditional ingredients shall be the name of herbal ingredients which are written in accordance with regulations in Clause 3 Article 16 herein and have the phrase “traditional ingredients” added before the Vietnamese name of herbal ingredients.

6. The name of herbal ingredients shall be written in accordance with regulations in Clause 3 Article 16 herein.

7. The name of semi-finished herbal medicines shall be written in accordance with regulations in Clause 4 and Clause 5 Article 16 herein.

8. The name of semi-finished drugs (excluding semi-finished herbal medicines) shall be written in accordance with regulations in Clause 6 Article 16 herein.

Article 15. Precautions and recommendations

1. The following precautions and recommendations must be written on labels and package inserts of drugs:

a) The text "Keep away from children" and "Read instructions carefully before use";

b) For prescription drugs:

- On the label of the secondary package: On the upper left corner of the drug name must have the symbol "Rx" and the text “Prescription drugs”;

- On the package insert: On the upper left corner of the drug name must have the symbol "Rx" and the text “This drug is taken with prescription only".

c) For controlled drugs or other drugs:

- Radioactive drugs must have the text “RADIOACTIVE DRUG” written in a bold and uppercase type;

- Drugs on the list of toxic drugs announced by the Ministry of Health must have the text “THUỐC ĐỘC” (“TOXIC DRUG”) written in a bold and uppercase type;

- Drugs used to serve a health program of the State must have the text “For a health program, not for sale”;

- Drugs used as emergency aid or humanitarian aid must have the text “As emergency aid or humanitarian aid, not for sale”;

- The label of drugs used for clinical testing purpose must have the text “Do not use for any purposes other than the clinical testing”;

- Biosimilars must have both name of the biosimilar and name of the reference biologic.

d) Other precautions and recommendations for each type of drug:

- The administration route of injectable drug must be written briefly or in full on the label, including: "intramuscular injection", "subcutaneous injection", "intravenous injection", "intravenous infusion", etc.

- The text “eye drops” shall be written on labels of eye drops and eye ointment respectively; “Nose drops” on labels of nose drops; “Ear drops” on labels of ear drops;

- The text “External drugs” shall be written on labels of topical drugs; “No injection" on bottles of oral drugs;
- Drugs that must be shaken well before use (E.g.: multi-dose packages of drugs in the form of blends, powder and granule that must be reconstituted before use or easily deposited or separated into layers after being dissolved) must have the text "Shake well before use".

2. Format of precautions and recommendations:

a) The text and symbols must be clearly printed on secondary packages or secondary labels and package inserts. Contents must be clear enough to be read in normal conditions;

b) On package inserts: Precautions and recommendations prescribed in Points a, b and c Clause 1 of this Article, except for the symbol “Rx”, must be written right below the drug name;

c) All the precautions of the drug must be written.

Article 16. Composition of drugs and semi-finished drugs

1. General provisions:

a) Secondary package labels of drugs and semi-finished drugs:

- The names of active ingredients or herbal ingredients and concentrations or contents thereof in a smallest dose or package of drugs or semi-finished drugs shall be specified;

- For vaccine: Active ingredients in a dose unit shall be specified;

- For biologics: Contents of the biologic shall be expressed according to the weight unit, the unit of biologic activity or the international unit of each biologic;
- For traditional drugs, herbal drugs, semi-finished traditional rugs and semi-finished herbal drugs: Names of herbal ingredients shall be Vietnamese names. Their scientific names are not required on the labels;

- Composition, contents, weights, volumes or concentration of recipients is not required on the labels;

- Labels of traditional drugs on the list of State secrets and labels of family remedies as recognized by the Ministry of Health are allowed to omit certain herbal ingredients and contents or weights thereof. In such case, secondary package labels must have the text “The formula is state secret” or “The formula is family secret”.

b) Primary package labels of drugs and semi-finished drugs:

- If the drug or semi-finished drug contains from one to three active ingredients or herbal ingredients, all active ingredients or herbal ingredients shall be specified in accordance with regulations in Point a of this Clause;

- If the drug or semi-finished drug contains more than three active ingredients or herbal ingredients, names of active ingredients or herbal ingredients are not required on primary package labels. Active ingredients or herbal ingredients and contents thereof may be also specified on labels in accordance with regulations in Point a of this Clause;

- If drug is in a liquid form, the drug labels must have the volume in a smallest package unit.

c) Package inserts:

- The names of active ingredients or herbal ingredients and concentrations, weights or contents thereof in a smallest dose or smallest package unit must be specified on package inserts. The text “Active ingredients:” must be specified before names of active ingredients or herbal ingredients;

- All excipients in the drug formula must be specified and the “Excipients:” must be also specified before names of excipients. The excipients that evaporate or disappear during the manufacturing process may be omitted. The weights, volumes, contents or concentrations of excipients are not required;

- The package insert of vaccines must have all active ingredients in a dose unit;

- For biologics: Contents of the biologic shall be expressed according to the weight unit, the unit of biologic activity or the international unit of each biologic;

- For traditional drugs and herbal drugs: Both Vietnamese name and scientific name of each herbal ingredient shall be specified. The scientific name of herbal ingredient shall be italicized in the brackets right after its Vietnamese name;

- Package inserts of traditional drugs on the list of State secrets and labels of family remedies as recognized by the Ministry of Health are allowed to omit certain herbal ingredients and contents or weights thereof. In such case, package inserts must have the text “The drug recipients is the State secret” or “The drug recipients is the traditional secret”.

2. Expression of active ingredients and excipients:

a) Name of an active ingredient or excipient shall be its international nonproprietary name or scientific name;

b) It is not required to translate names of active ingredients and excipients into Vietnamese language.

3. Expression of herbal ingredients and traditional ingredients:

a) Vietnamese name:

- Names of herbal ingredients and traditional ingredients shall be conventional names in Vietnamese language as specified in the Pharmacopoeia of Vietnam or in the lists of drugs and medicinal ingredients announced by the Minister of Health;

- If Vietnamese names of herbal ingredients are not available in the Pharmacopoeia of Vietnam or the lists of drugs and medicinal ingredients announced by the Minister of Health, Vietnamese names of these herbal ingredients as specified in the book (“Traditional plants and ingredients of Vietnam”) of Mr. Do Tat Loi, or the book “1000 medicinal plants and animals” of the National Institute of Medicinal Materials. In such cases, names of herbal ingredients shall be decided by the Minister of Health according to the counseling of the Advisory Council for drug registration certification affiliated to the Ministry of Health.

- If the names of imported herbal ingredients cannot be translated into Vietnamese language, the names in the exporting country (or the country of origin) and their scientific names shall be written;

- If more than one part of the plant is used as herbal ingredients of traditional ingredients, the parts must be specified. Example: Tam sen, Hoa hoe, Kim ngan hoa.

b) Scientific names (Latin names):

- Scientific names of herbal ingredients or traditional ingredients shall be their scientific names in italics in the Pharmacopoeia of Vietnam or in the lists of herbal ingredients and traditional ingredients announced by the Minister of Health;

- If scientific names of herbal ingredients and traditional ingredients are not available in the Pharmacopoeia of Vietnam or in the Minister of Health’s lists of herbal ingredients and traditional ingredients, their scientific names in foreign pharmacopoeias shall be written.

4. Expression of bone glue, type and formula of bone glue:

a) Expression of the bone glue:

- Name of the bone glue, type and composition of the bone glue, concentrations, contents or weights of herbal ingredients in the bone glue must be specified;

- If the bone glue has a trade name, this trade name and names of herbal ingredients in the bone glue shall be specified in accordance with regulations in Clause 3 of this Article;

- In case there is no trade name, the word “bone glue” shall be specified right before the name of herbal ingredient (if the bone glue contains the only ingredient) or the phrase “bone glue mixture” shall be specified right before names of herbal ingredients (if the bone glue contains multiple ingredients).

b) Expression of type of the bone glue:

- Type of the bone glue must be clearly specified. There are three types of the bone glue, liquid, solid and dried glue according to Vietnam’s pharmacopoeia;

- If the type of the bone glue is not identified, the moisture content limit and name of the bone glue or the ratio of bone glue and initial herbal ingredients must be specified.

c) Expression of formula of the bone glue:

- If the treatise of Vietnam’s pharmacopoeia or a foreign pharmacopoeia recognized by the Ministry of Health provides criteria for quantifying contents of active ingredients or compounds, name of the bone glue must be written together with the contents (%) of active ingredients or compounds quantified in each herbal ingredient;

- If the treatise of Vietnam’s pharmacopoeia or foreign pharmacopoeias recognized by the Ministry of Health does not provide criteria for quantifying contents of active ingredients or compounds, name of the bone glue must be written together with the weight of corresponding initial herbal ingredients or the ratio of the bone glue and the initial herbal ingredients (initial herbal ingredients are herbal ingredients qualified for medicinal use);

- If the solvent used for extracting herbal ingredients to manufacture bone glue is not ethanol, water or a mixture of ethanol and water, the name of the bone glue must be written together with that of the solvent.

5. Expression of name of semi-finished herbal medicines (excluding bone glue):

a) The name of semi-finished herbal medicine and the composition, concentrations, contents or quantities of herbal ingredients contained in the semi-finished herbal medicine must be fully specified;

b) Expression of the name of semi-finished herbal medicine:

- If the semi-finished herbal medicine has a trade name, this trade name shall be written together with the name of every herbal ingredient contained in the semi-finished herbal medicine in accordance with regulations in Clause 3 of this Article;

- If there is no trade name, the name of herbal ingredient shall be written according to regulations in Clause 3 of this Article (if the semi-finished herbal medicine contains the one herbal ingredient) or the text “mixture of herbal ingredients” shall be written (if the semi-finished herbal medicine contains multiple herbal ingredients). The form of the semi-finished herbal medicine (such as powder or granule) must be also written right before the name of herbal ingredient or the text “mixture of herbal ingredients”.

c) Expression of formula of the semi-finished herbal medicine:

- If the treatise of Vietnam’s pharmacopoeia or a foreign pharmacopoeia recognized by the Ministry of Health provides criteria for quantifying contents of active ingredients or compounds, name of the semi-finished herbal medicine shall be written together with the contents (%) of active ingredients or compounds quantified in each herbal ingredient;

- If the treatise of Vietnam’s pharmacopoeia or foreign pharmacopoeias recognized by the Ministry of Health does not provide criteria for quantifying contents of active ingredients or compounds, name of the semi-finished herbal medicine must be written together with the weights of corresponding initial herbal ingredients or the ratio of the semi-finished herbal medicine and the initial herbal ingredients (initial herbal ingredients are herbal ingredients qualified for medicinal use).

6. Expression of name of semi-finished drugs (excluding semi-finished herbal medicines):

a) The name of semi-finished drug and the composition, contents, concentrations or weights of active ingredients contained in the semi-finished drug must be sufficiently specified; b) Expression of the name of semi-finished drug:

- If the semi-finished drug has a trade name, this trade name shall be written together with the name of every active ingredient contained in the semi-finished drug in accordance with regulations in Clause 2 of this Article;

- If there is no trade name, the name of active ingredient shall be written according to regulations in Clause 2 of this Article (if the semi-finished drug contains the one active ingredient) or the text “mixture of active ingredients” shall be written (if the semi-finished drug contains multiple active ingredients). The form of the semi-finished drug (such as powder or granule) must be also written right before the name of active ingredient or the text “mixture of active ingredients”.

c) Expression of formula of the semi-finished drug: Regulations on semi-finished drugs in Clause 1 of this Article shall be applied.

7. Measurement units:

Contents, concentrations, weights and volumes are expressed as weight units, volume units, activity units or other common measurement units. To be specific:

a) Weight units: gram (g), milligram (mg), microgram (μg or mcg), or kilogram (kg). The weight below 1 mg shall be expressed as a decimal fraction (e.g. 0.25 mg);

b) Volume units: Milliliter (ml), micro liter (μl or mcl), or liter (l or L). The volume below 1 ml shall be expressed as a decimal fraction (e.g. 0.5 ml);

c) Other measurement units:

- International activity units may be used for special active ingredients;

- If internationalized medical measurement units such as IU and other conventional units of activity of certain special active ingredients may cause misinterpretation if translated into Vietnamese language, they may be kept unchanged.

d) Where the form of an active ingredient is different from the form used for dose determination, the secondary package label and package insert must have the conversion of the concentration, content or weight of that active ingredient to the form used for dose determination. The form of an active ingredient is either base, salt, hydrate or another form.

Article 17. Dosage form

1. The dosage form must be clearly specified and might be: tablets, hard capsules, solution for injection, powder for solution for injection, suppositories (specify inserting positions), powders, granules and other types of drugs according to the Pharmacopoeia of Vietnam or common International Pharmacopoeias.

2. In addition to the information specified in Clause 1 of this Article, package inserts must have the additional information below:

a) External features such as color, size, form, shape or other external signs (if any);

b) Whether scored tablets should be split in half or not;

c) Information about pH and osmotic concentration (if any).

Article 18. Indications

Indications of a drug must be conformable with its dosage form and administration route. The indications must be clear, particular, and must specify:

1. Purposes of the drug: whether the drug is used for curative, supportive care, preventive or symptom relief purpose.

2. Drug users (if any): specify the drug indications applied to each type of drug users; drug users may be sorted by age or group of age.

3. Additional conditions for safe and effective use of drugs (if any), e.g. the drug must be combined with other drugs or methods to improve the effectiveness or reduce side effects during the course of treatment.

Article 19. Dose and usage instructions

1. Dose:

a) Specify the recommended dose for each administration route or/and each indication or method for drug use.

- Specify the interval between drug uses in a day, method to achieve best result (e.g. drink a lot of water or take before eating);

- Specify the recommended minimum and maximum total dose; specify the limited use duration of drugs (if any).

b) Specify the doses and directions applied to adults and children (if any). Doses for children must be sorted by age group or body weight;

c) Specify the doses for special users such as children, elderly people, patients suffering from renal failure, liver failure, etc.

2. Usage instructions:

a) Specify the administration route, administration time, and directions in order to achieve best results:

- If the drug is injectable, the preparation or reconstitution for injection and injection method must be specified e.g. intramuscular injection, intravenous injection, infusion, subcutaneous injection, deep subcutaneous injection, deep intramuscular injection, or other method; injection or infusion rate shall be specified if required;

- Directions for drug use in special cases of precautions or recommendations as mentioned in Point d Clause 1 Article 15 herein must be specified;

- Herbal drugs: specify the usage instructions (water, tools, method, temperature, and time), contraindications and cautions.

b) For prescription drugs:

In addition to directions in Point a Clause 2 of this Article, directions for children or special drug users and recommendations (if any) must be specified as follows:

- Doses shall be specified by group of age. A dose is calculated according to body weight or body surface area (mg/kg or mg/m2) or divided into intervals. If a drug is used for children with similar indications as those applied to adults, the dose and usage applied to children must be specified;

- If there is no indication for one or all age group of children, the dose and usage must be specified in either of the following manners:

+ The safety and effectiveness of drugs for children at certain ages (expressed as months or years) or group of patients (e.g. by gender, body weight) is not proven;

+ The drug is not recommended for children at certain ages (express as months or years) or group of patients (e.g. by gender, body weight) due to its safety and effectiveness;

+ The drug should not be used for infant patients (from age x to y), (or other groups of patients e.g. by gender, body weight) with regard to certain indications.

- Recommendations with regard to dose and usage (if any):

+ When to stop using drugs? What to do when forgetting to take a dose? What foods and drinks to use with drugs? When to reuse drugs after a course of treatment?;

+ Adjustment of dose when combining with other drugs; adjustment of dose to the patient’s conditions (depending on the clinical symptoms and signs and/or kidney or liver function test results);

+ Preventive measures for some specific adverse reactions (e.g. taking antiemetics before using antineoplastic drugs); mild adverse reactions that are common when taking the first dose;

+ Recommendations about drug administration for health officials or patients (if any); information about other routes of administration, especially through gastric sonde (if information is available). If the administration route is other than the gastrointestinal tract, the injection or infusion rate must be specified.

3. Special notes for treatment of drugs before and after use:

Instructions for treatment of drugs before and after use must be specified as follows:

a) Treatment of drugs before use (if any):

- Specify the preparation of drugs before use (reconstitution or dilution);

- Specify measures for protecting drug preparer;

- Specify external features of drug before being reconstituted or diluted, and features of reconstituted drug.

b) Treatment of drugs after use (if any):

- Specify precautions for discarding drugs after use in certain cases such as cytotoxic drugs, preparations that contain live bacteria and other cases where specific regulations apply;
- If there is no usage instruction or special treatment precaution for health officials, the text “No precaution for treatment for drugs after use” shall be written.

Article 20. Contraindications

1. If there are contraindications, the cases in which drugs must not be used must be specified.

2. If the contraindications involve children, the ages of children (expressed as months or years) or other group of patients (e.g. by gender or body weight) must be specified.

Article 21. Warnings and cautions

1. Specify the cautions when using drugs and recommendations about use of drugs for children and chronic disease patients (if any).

2. Conditions that need cautions:

a) The test results or conditions of the patients that need assessing before using drugs; necessary measures for minimizing the risk of adverse reactions while using drugs;

b) Serious adverse reactions that need to be reported to health officials;

c) The preventive measures and early detections of symptoms of serious adverse reactions;

d) The risks related to the beginning or suspension of treatment;

dd) The subjects likely to have adverse reactions to the group of drugs (usually serious or common);

e) The clinical symptoms, signs, or test results that need monitoring during the course of treatment. The tests affected by drug use;

g) The warnings and cautions for infant patients related to safety of long-term drug administration (such as influence on the child’s growth, mental development, sexual development, etc.);

h) Warnings related to excipients or drug residues that cause adverse drug reactions or influences as proven. Warnings related o these excipients must be specified in this part or in the part of warnings and cautions when using drugs;

i) Warnings related to ethanol in the drugs;

k) The risks related to inaccurate administration route.

3. For biosimilars:

Specify warnings about risks related to replacement or conversion between reference preparations and biosimilars during the treatment.

Article 22. Using drugs during pregnancy and breastfeeding

1. Using drugs during pregnancy:

a) Provide information about the influence of drugs on pregnant women. If such information is not available, the text “There is no controlled data in human pregnancy. The drug is only recommended for use during pregnancy when benefit outweighs risk” must be specified;

b) The recommendations for pregnant women must include recommendations about the use of drugs by women suspected of pregnancy, women practicing birth control, and the use of drugs in various stages of pregnancy;

c) Provide additional information about the influence of drugs on the fetus, including information about possible influence of drugs on the fetus. The unavailability of information about toxicity of drugs upon the fetus must be specified;

d) Provide recommendations about monitoring of the fetus and newborn babies whose mother uses drugs during pregnancy (if information is available).

2. Using drugs during breastfeeding:

Recommendations for breastfeeding must specify whether the breastfeeding must be stopped or may be carried on, whether the treatment must be stopped or may be carried on (if sufficient information is available).

Article 23. Influence of the drug on ability to drive or operate machinery

1. The level of influence must be specified: no influence or inconsiderable influence, mild influence, medium influence, or serious influence.

The text “There is no proven influence of the drug on ability to drive or operate machinery” must be written.

2. Additional important information (if any) must be specified such as the time the effects decreases and the effectiveness of drugs when resuming the drug use.

Article 24. Drug interactions and incompatibilities

1. Drug interactions:

a) Specify the reactions of the drug with other drugs and other reactions (e.g. with alcohol, foods, etc.) that may affect the effectiveness of the drug. To be specific:

- Specify information about drug interactions with clinical significance based on their pharmacodynamic properties and pharmacokinetic studies;

- Specify consequences of drug interactions such as: clinical signs (if any), influence of drug interactions on drug concentration in blood, pharmacokinetic data of drugs or active metabolites of drugs; influence of drug interactions on test results. Treatment for minimizing consequences of drug interactions must be also specified;

- Specify the mechanism of interaction if the mechanism is clear. The unavailability of drug interaction studies must be specified;

- Other serious drug interactions such as the adsorption of the drug onto its package or syringe.

b) The contraindications of herbal drugs or traditional drugs must be specified (if any). E.g.: if the drug tends to cause damp-heat, raw, cold and frozen foods should be abstained; if the drug tends to cause damp-cold, hot and spicy foods should be abstained.

2. Drug incompatibilities:

a) Specify information about chemical and physical incompatibilities with other drugs when they are mixed or used simultaneously, especially drugs reconstituted or diluted before use for intravenous infusion;

b) If the information about drug incompatibilities is unavailable, the text “There is no study on drug incompatibilities. Do not mix this drug with other drugs") shall be specified.

Article 25. Adverse drug reactions

1. Specify the cases in which drug use must be suspended, the cases in which adverse drug reactions must be reported to the physician or pharmacist, or reported to the National Center of Drug Information & Adverse Drug Reactions.

2. Apart from the information specified in Clause 1 of this Article, information about adverse drug reactions according to the summary (if any) must be added as follows:

a) Adverse reactions shall be sorted by frequency: very common (ADR ≥ 1/10), common (1/100 ≤ ADR < 1/10), not common (1/1000 ≤ ADR < 1/100), rare (1/1000 ≤ ADR < 1/10000) and very rare (ADR < 1/10000);

Classification of adverse reactions of herbal drugs or traditional drugs by frequency is not required.

b) If the users are children, it is required to describe the children’s ages and seriousness of adverse reactions (if any); clinical differences in drug safety between adults and children (or between certain age groups). If such information is already mentioned in another part of the package insert, it must be referred to;

c) Every clinical difference in frequency, seriousness of reactions, ability to recover, and the cases that need monitoring in special users (e.g. elderly people, patients suffering from liver failure, renal failure, and other diseases) must be specified.

3. If there is no record or evidence about drug adverse reactions, the text “There is no reported case of adverse drug reactions” and “Any adverse drug reactions should be immediately reported to the physician or pharmacist” shall be specified.

Article 26. Overdose and treatment

1. Overdose:

a) Specify the symptoms and signs of overdose: Symptoms and signs of acute poisoning and possibility to cause permanent injuries (if any);

b) If the information about drug overdose is unavailable, the text “There is no record of drug overdose. Do not use this medicine in larger mounts than recommended” shall be specified.
2. Treatment for overdose:

a) Specify the measures or treatment for overdose, including monitoring and using adrenergic agonists, antagonists, antidotes, or enhanced drug excretion. If such information is not available or not sufficient, there must be the text "Keep monitoring to respond in time";

b) Provide information for special users such as: elderly people, pregnant and breastfeeding women, children, patients having kidney failure, liver failure, or other diseases (if any).

Article 27. Pharmacological and clinical effects

1. Pharmacodynamics: The following information about pharmacodynamics must be specified:

a) Pharmacological group and ATC number (if any);

b) Description of the reaction mechanism corresponding to the approved indications;

2. Pharmacokinetics: The following information about pharmacokinetics must be specified:

a) Pharmacokinetic properties of drugs (absorption, distribution, metabolism, elimination, and other properties) corresponding to the recommended dose, concentration, and dosage form;

b) Description of the differences between the factors (such as ages, genders, body weights, smokers and non-smokers, patients suffering from kidney failure or liver failure) that influence the pharmacokinetics. If such influences are clinical, they must be quantified;

c) The relationship between the dose, concentration, pharmacodynamics (including primary and secondary criteria, and side effects) and characteristics of the test subjects;

d) With regard to infant patients: summarize results of pharmacokinetics study on children at various ages and comparison to adults (if any). Specify the dosage form used for pharmacokinetics study on children, the uncertainties due to limited use of drugs on children.

3. Results of clinical and non-clinical tests (if any):

a) Summary of primary results of major clinical tests that support the approved indications (if any), including:

- Description of primary characteristics of the sample;

- Primary criteria;

- Secondary criteria (if any);

- Study results related to primary criteria.

b) Provide basic information concerning non-clinical studies (if any).

Article 28. Smallest package unit and package contents

1. Common smallest package units are as follows:

a) Drugs in the form of tablets: The smallest package unit shall be tablet. With regard to drugs in the form of Chinese tablets, the smallest package unit shall be pack, jar, bottle or bag;

b) Drugs in liquid form: The smallest package unit shall be jar, bottle, vial, pack, prefilled syringe or injection device;

c) Drugs in form of powder that have to be reconstituted before use: The smallest package unit shall be jar, bottle, vial, pack, prefilled syringe or injection device;

d) Drugs in the form of powder or granule: The smallest package unit shall be jack, bottle, jar or pack;

dd) Drugs in the form of cream, ointment or gel for external use: The smallest package unit shall be tube, jar or pack;

e) Drugs in the form of transdermal patches: The smallest package unit shall be patch;

g) Drugs in the form of spray or aerosol: The smallest package unit shall be spray bottle, metered dose inhaler or drug jar of aerosol nebulizer;

h) Drugs in the form of kits: The smallest package unit shall be the kit;

i) Herbal drugs: The smallest package unit shall be pack, bag or box;

k) Medicinal ingredients: The smallest package unit shall be bag, pack, box, bottle, jar, or vial.

2. Expression of package contents:

a) The package contents of a drug must be expressed as natural numbers of the quantity, net weight, or true volume of drugs contained in a commercial package;

b) If a commercial package contains multiple package units, the content of each package and quantity of packages must be specified;

c) Every equipment accompanied to the drug such as injection needle, syringe, measuring spoon, measuring cup, aerosol device and other supportive tools contained in the commercial package (if any) must be specified.

3. If the drug is on the list of controlled drugs which are narcotic drugs, psychotropic drugs, or drug precursors, the secondary package shall not contain more than 100 smallest package units.

Article 29. Batch number, manufacturing date and expiry date

1. Batch number:

Batch number shall be expressed fully as “Lot number” or briefly as “LOT” and information about the batch number. The information and composition of the batch number is decided by the manufacturer.

2. Manufacturing date and expiry date:

a) The manufacturing date and expiry date shall be written fully as “Manufactured Date”, “Expired Date”, or briefly as “MFG”, “EXP" before information about the manufacturing date and expiry date;

b) The manufacturing date and expiry date shall be expressed in any of the following format: [dd/mm/yy], [dd. mm. yy], [dd-mm-yy], [dd mm yy], or [ddmmyy];c) Where the secondary package contains diluents vials or reconstitution kit:

- If the drug and its component parts share the same manufacturing date and expiry date, that manufacturing date and expiry date shall be specified on the label of the secondary package;

- If the expiry dates of the drug and its component parts are different, the shortest expiry date or the expiry date of every component part shall be specified.

3. Expression of manufacturing date, expiry date and batch number:

a) Where the manufacturing date, expiry date and batch number are written on in a foreign language:

- If the manufacturing date, expiry date and batch number on the original label are written in a foreign language, the secondary label must contain the text: “manufactured date (MFG), expired date (EXP), Lot number (LOT) to see the manufactured date, expired date, lot number in foreign languages in the original label.

E.g.: see “Mfg Date”, “Exp Date”, “Lot.No.” on the original label.

- If the expiry date on the primary package label is expressed as “mm/yy” and the expiry date on the secondary package label is fully expressed as “dd/mm/yy”, the expiry date expressed on the secondary package label shall apply;

- If the expiry date on both the primary package label and secondary package label is expressed as “mm/yy” but:

+ the manufacturing date on the original label is fully expressed as “dd/mm/yy”, the expiry date on the secondary label shall be calculated and expressed according to the manufacturing date on the original label;

+ the manufacturing date on the original label is expressed as “mm/yy”, the expiry date shall be the last day of the expiry month and the secondary label must have the text “expiry date is the last day of the expiry month”.

b) If the primary package label is so small that the batch number or expiry date has to be written in series of numbers instead of with the text “MFG Lot” and “EXP” as prescribed in Clause 1, Clause 2 of this Article, such information must be fully written on the secondary package as prescribed;

c) The package insert must contain the following information:

- Expiry date of the drug as a period from the manufacturing date;

- The useful life after opening the primary package for the first time for drugs without divided dose such as eye drops, nose drops, ear drops, ointment, gel and orally administered multi-dose liquid drugs or tablets bottled in large quantities (if any);

- The useful life after preparation for drugs in the form of powder, granule that must be reconstituted before use (e.g. injection or oral administration).

Article 30. Change of expiry dates of labeled drugs because of national defense and security, epidemic control or disaster recovery need

Because of national defense and security, epidemic control or disaster recovery need, Minister of Health may decide to change the expiry dates of labeled drugs and stipulate the way to express the expiry date in each specific case on the basis of drug quality, comparison between benefits and risks or lack of domestic supply of drugs.

Article 31. Storage conditions and quality standards

1. The label of drugs or medicinal ingredients and package inserts must:

Specify the storage conditions in terms of temperature (expressed as0C), humidity, and lighting or other special storage conditions in order to avoid affecting the drug quality during storage and transport (if any).

2. The package insert must specify storage requirements with regard to the cases mentioned in Paragraph 2 and 3 Point c Clause 3 Article 29 herein.

3. Expression of quality standards:

The secondary package label and package insert must have quality standard of the drug or medicinal ingredient. To be specific:

a) If the drug or medicinal ingredient follows quality standards of the Pharmacopoeia of Vietnam or a foreign pharmacopoeia recognized by the Ministry of Health, the quality standard shall be specified according to the full name in Vietnamese language of the pharmacopoeia or the abbreviated name in Vietnamese language of the Pharmacopoeia of Vietnam or the abbreviated name in English of the foreign pharmacopoeia. The version or publishing year is not required;

b) If the drug or medicinal ingredient follows a basic standard, the text “Primary Standards” shall be specified.

Article 32. Registration number and import license number

1. Registration number in Vietnam:

Specify “Registration number:” or “SĐK:” without information specified when applying for the registration number. Before selling drugs on the market, the registration number issued by the Ministry of Health to the drug or medicinal ingredient granted the Certificate of registration must be added.
2. Import license number:

Specify "Import license number" or “GPNK:” without information specified when submitting the application for license to import drugs. Before selling drugs on the market, the import license number issued by the Ministry of Health to the drug or medicinal ingredient without the Certificate of registration must be added.

Article 33. Names and addresses of manufacturer, preparation and processing factory, importer and relevant entities (if any)

1. General provisions on name and address of manufacturer and importer on the drug label and package insert:

a) Secondary package labels of drugs and medicinal ingredients:

- If drugs are manufactured in Vietnam: write the role, name and address of the drug manufacturer;

- If medicinal ingredients manufactured in Vietnam or imported: write the name and address of manufacturer of medicinal ingredients;

- If drugs are imported: write the role, name and address of the drug manufacturer; the name and address of the drug importer.

b) Primary package labels: Full name or business name of the manufacturer shall be specified as long as the manufacturer is identified.

If a drug has more than one manufacturer:

- Specify every manufacturer of the commercial drug; or

- Specify the name of the manufacturer responsible for the release of the batch.

c) With regard to traditional drugs prescribed in Clause 1 and Clause 2 Article 70 of the Law on Pharmacy and drugs produced or prepared within health facilities as prescribed in Clause 2 and Clause 3 Article 85 of the Law on Pharmacy:

- On the secondary package label: write the name and address of the health facility that prepare or produce drugs;

- On the primary package label: write the full name or business name of the health facility. d) Labels of drugs prepared according to prescriptions for sale at drugstores in accordance with regulations in Point b Clause 1 Article 47 of the Law on Pharmacy must have the name and address of the drugstore;

dd) Package inserts: write the role, name and address of manufacturers. If drugs are imported, the name of manufacturing country must be translated into Vietnamese unless Vietnamese name is not available;

e) Apart from the name and address of the manufacturer and importer, the drug label and package insert may contain the roles, names and addresses of relevant entities such as the registrant, distributor, brand owner, drug owner or relevant entities.

2. Expression of role of entities responsible for the drug:

a) Manufacturer:

- If a drug has the one manufacturer: the role shall specified by the text “Manufacture of drugs:”
- If a drug has more than one manufacturer: the role of each manufacturer must be specified either as “Manufacturer of semi-finished drugs”, “Primary packaging facility” or “The entity responsible for release of the batch”;

- The name of manufacturer shall be the name specified in the Certificate of eligibility for pharmacy business issued by a regulatory authority.

b) Importer: write the role as “Importer”;

c) Other entities: specify the role as “Distributor”, “Drug owner”, “Brand owner" or other entities (if any).

3. Expression of name and address of manufacturer:

a) If a drug has more than one manufacturer, names and addresses of all manufacturers must be written. Their names must be of the same size and on the same plane;

b) If drugs are processed by another entity, the label shall have the text "Manufactured by [processor s name and address] under contract with [hirer s name and address]”. The processor s name and address must be on the same plane of the label and have the same size as the hirer s;

c) Labels of drugs manufactured under technology transfer must have the text “Manufactured by [transferee’s name and address] by adopting the technology transferred from [transferor’s name and address]”). The transferor s name and address must be on the same plane of the label and have the same size as the transferee’s.

4. Expression of name and address of importer: a) Fully specify the text là “Importer: name and address”) on the label; or

b) Briefly specify “Importer: name and address”.

Specify “Importer” without the importer s name. The importer s name and address must be added before selling drugs on the market.

5. Other provisions on expression of name and address:

a) Expression of names of relevant establishments:

- Name of a domestic establishment: write the name specified in the Certificate of eligibility for pharmacy business, the certificate of enterprise registration or the investment certificate issued by a regulatory authority;

Names of health facilities shall be the names specified in the license to provide healthcare services in accordance with regulations of the Law on medical examination and treatment.
- Name of a foreign establishment: write the name specified in the drug certificate or GMP certificate, or relevant legal document issued by the competent authority in the home country.

Particularly, name of a foreign manufacturer shall be the same as the name specified in the drug certificate or GMP certificate issued by the competent authority in the home country.

b) Expression of addresses of relevant establishments:

- Address of a domestic manufacturer: specify the address which is the business location specified in the Certificate of eligibility for pharmacy business. The address of the enterprise’s head office may be also specified;

- Address of a manufacturer must include the house number, name of the street or neighborhood, commune or ward, district, province or centrally-affiliated city;

Particularly, the address of a health facility shall be the address of its manufacturing factory as specified in the License to provide healthcare services in accordance with regulations of the Law on medical examination and treatment.

- For imported drugs:

The address of the manufacturer shall be the address of its manufacturing factory as specified in the drug certificate or GMP certificate issued by the competent authority in the home country.

c) The names, addresses, logos of relevant entities specified in the label or package insert as regulated in this Clause must not be larger in size than those of the manufacturer, unless it is the drug owner as proven;

d) If the label contains the name, address, and/or logo of the distributor, the distributor’s name, address, and logo must not be larger in size than the manufacturer’s;

dd) If the manufacturer is a member or dependent unit of an organization such as a company, general company, corporation, association, or another organization, its name, address, brand, trademark, and other contents may be written on the label if permitted by such organization as long as the address of the factory where drugs are manufactured is specified.

E.g.: Drugs are manufactured at factory A of company B, the label may have the text “"Company B, branch, manufactured at A”.

Article 34. Origins of drugs and medicinal ingredients

1. Determination of origins of drugs and medicinal ingredients:

a) Origins of drugs and medicinal ingredients shall be determined in accordance with the Law on Commerce, legislative documents on guidelines for the Law on Commerce with regard to goods origins and relevant legislative documents;

b) The entities responsible for labeling as prescribed in Article 6 herein shall determine and specify origins of their drugs and medicinal ingredients in honest and genuine manner and in conformity with the law regulations on good origins or international treaties to which Vietnam is a signatory.

2. Expression of origins of imported drugs and medicinal ingredients:

Origins of drugs or medicinal ingredients shall be written on secondary packages as follows:

a) The phrase "origin:" or "manufactured in:" or “manufactured by:” and the name of the country or territory in which the drug or medicinal ingredient is manufactured;

The name of the country or territory in which the drug or medicinal ingredient is manufactured must be the full name.

b) If the drug or medicinal ingredient origin is the same as the country or territory in which it is manufactured, only the country s name in Vietnamese (or English if Vietnamese name is not available) is required;

c) If the drug or medicinal ingredient origin is different from the country or territory in which it is manufactured, full information about drug or medicinal ingredient origin as set out in Point a Clause 2 of this Article must be written.

3. For drugs or medicinal ingredients manufactured in Vietnam for domestic sale, if the manufacturer’s address is already written, the drug or medicinal ingredient origin may be omitted.

Article 35. Other contents on labels

1. In addition to the compulsory information prescribed in this Circular, other information may be written on the label and package insert included in the application for registration or license to import the drug without registration number or the drug label in the case prescribed in Clause 1 or Clause 2 Article 11 herein provided it must satisfy regulations in Clause 3 of this Article.

2. In addition to the compulsory information prescribed in this Circular and before selling drugs on the market, the responsible entity may write other information on the drug label and/or package insert which has been approved by a regulatory authority without giving a notification and obtaining the approval from a regulatory authority provided that it must satisfy the requirements in Clause 3 of this Article. In such case, the responsible entity shall ensure the accuracy of additional information. To be specific:

a) Affix or alter anti-fraud stamps as well as other security warnings and anti-counterfeit contents on drug labels to help fight against counterfeit products or recognize their products;

b) Change the form or color of the package insert; the size of the secondary package label or the primary package label;

c) Add or alter the telephone number, zip code, web address or email address of any relevant entity responsible for the drug or of the brand owner;

d) Add or alter the symbol ® behind the drug name or behind the company’s name or logo; change logo of any relevant entity responsible for the drug;

dd) Change the position of the registration number or import license number, the position of the secondary label, or the position of batch number, expiry date or manufacturing date on the label;

e) Add information in another language which is translated from the information in Vietnamese language as approved by the Ministry of Health according to the application for drug registration or the application for the license to import drugs without registration number.

3. Provisions on additional information on the label:

a) Additional information must be lawful, truthful, and accurate, and reflect the true nature and effects of drugs, must not be advertising information and must not block or falsify compulsory information on the label, and ensure that the compulsory information is conformable with the label approved by a functional unit of the Ministry of Health;

b) Additional information must not be:

- Information or images prohibited in advertising as regulated in Article 8 of the Law on Advertising;

- Information prescribed in Clauses 2, 3, 4, 5, 6, 10, 11, 12, 13, 14, 15 and 16 Article 126 of the Decree No. 54/2017/ND-CP;

- Information and images prescribed in Clause 2 Article 18 of the Decree No. 43/2017/ND-CP;

- Information or images about the bioequivalence or clinical equivalence between biosimilars and reference biologics.

c) The information in another language as prescribed in Point e Clause 2 of this Article must be conformable with the information in Vietnamese language. The text or numbers in another language must not block or be larger in size than those in Vietnamese language;

d) The label and package insert of drugs or medicinal ingredients manufactured in Vietnam and exported may have the information written in the language of the importer’s country as requested under the sale contract provided that it shall not falsify the information and the nature of drugs or medicinal ingredients.

Chapter IV

IMPLEMENTATIONORGANIZATION

Article 36. Effect

1. This Circular takes effect on June 01, 2018.

2. The Circular No. 06/2016/TT-BYT dated March 08, 2016 of the Minister of Health on drug labeling is annulled from the effective date of this Circular, except for regulations on labeling of in vitro diagnostic reagents, which shall remain effective until superseding issued documents.

Article 37. Transitional provisions

1. With regard to drugs or medicinal ingredients granted registration numbers or import licenses before this Circular comes into force:

a) They may be sold with the labels and package inserts approved by the Ministry of Health until the expiry dates of batches of drugs or medicinal ingredients manufactured or imported within the validity of the registration certificates or the import licenses granted before this Circular comes into force, except for the case prescribed in Point b Clause 1 of this Article.

b) With regard to drugs and medicinal ingredients on the List of toxic drugs and toxic medicinal ingredients enclosed with the Circular No. 06/2017/TT-BYT dated May 03, 2017 of the Minister of Health on promulgation of the List of toxic drugs and toxic medicinal ingredients; drugs which are on the List of OTC drugs enclosed with the Circular No. 23/2014/TT-BYT dated June 30, 2014 of the Minister of Health on promulgation of the List of OTC drugs but not on the List of OTC drugs enclosed with the Circular No. 07/2017/TT-BYT dated May 03, 2017 of the Minister of Health on promulgation of the List of OTC drugs (hereinafter referred to as the “Circular No. 07/2017/TT-BYT”), registrants or importers must classify, update and supplement relevant information as follows:

- Drugs or medicinal ingredients manufactured before this Circular comes into force: comply with regulations in Point a Clause 1 of this Article;

- Drugs or medicinal ingredients manufactured from the date of entry into force of this Circular: Update information concerning the classification of drugs or medicinal ingredients on labels and package inserts in accordance with regulations in this Circular before selling drugs or medicinal ingredients on the market within 12 months as from the date of entry into force of this Circular without giving any notification to the Ministry of Health, unless an application is submitted for modification of the certificate of registration related to the package insert of drugs granted registration number as regulated in the Ministry of Health’s Circular on registration of drugs and medicinal ingredients.

2. Applications for certificate of free sale or permission for import of drug without registration numbers submitted to units affiliated to the Ministry of Health and have not been granted before the effective date of this Circular, excluding drugs and medicinal ingredients mentioned in Clause 3 of this Article, shall be considered as follows:

a) The registrant or importer may submit additional documents about the label and package insert of the drug in accordance with this Circular in order to be considered and granted the registration number or license for import of drugs without registration number;

b) If no additional documents are submitted as prescribed in Point a of this Clause, the label and package insert may be considered under Circular No. 06/2016/TT-BYT, excluding the case prescribed in Point b Clause 1 of this Article;

Within 06 months from the day on which the certificate of free sale is issued, the facility responsible for drug labeling shall update the label and package inserts in accordance with this Circular in the form of registration of changes according to the Ministry of Health’s Circular on registration of drugs and medicinal ingredients, excluding the case prescribed in Point b Clause 3 Article 6 of the Circular No. 07/2017/TT-BYT.

3. With regard to applications for registration of drugs or medicinal ingredients in the form of registration of changes of certificate of free sale with regard to changes in label and package insert, which have been submitted to units affiliated to the Ministry of Health and have not been granted, the registrant or importer must supplement samples of label and package insert in accordance with regulations of this Circular before this Circular comes into force.

Article 38. Announcing information on package inserts

1. The Drug Administration of Vietnam shall review, update and announce information on package inserts of drugs, which are on the List of proprietary drugs and reference biologics announced by the Ministry of Health and have been granted registration numbers, on its website so that manufacturers and registrants may refer to when preparing applications for registration of generic drugs or bio-similars.

2. Any information added to package inserts of drugs on the proprietary drugs and reference biologics during the sale of drugs must be announced and published on the website of the Drug Administration of Vietnam within 45 days from the date on which such additional information is given approval.

3. Registrants and manufacturers shall update and supplement information on package inserts of generic drugs or bio-similars in conformity with corresponding guidelines on use of drugs on the List of proprietary drugs and reference biologics published on the website of Drug Administration of Vietnam as follows:

a) Package inserts of generic drugs or bio-similars must be conformable with package inserts of drugs on the List of proprietary drugs and reference biologics in terms of concentrations, contents, active ingredients, dosage form, and administration routes, excluding information about expiry dates, composition, quality standard, bioavailability, pharmacokinetics, adverse effects and clinical test results. The package insert of generic drugs or bio-similars must have more adverse effects than those of corresponding proprietary drugs and reference biologics, except adverse effects of proprietary drugs or reference biologics related to excipients which are not contained in such generic drugs or bio-similars;

b) Within 12 months from the date on which Drug Administration of Vietnam announced and published package inserts of proprietary drugs and reference biologics on its website as regulated in Clause 1, Clause 2 of this Article, registrants and manufacturers of generic drugs and bio-similars must update information on labels and package inserts of their products in conformity with package inserts of proprietary drugs and reference biologics in terms of the information mentioned in Clause 2 of this Article without giving notification to the Ministry of Health, unless otherwise requested by the Ministry of Health.

Article 39. Referenceterms

In case the legislative documents and regulations cited in this Circular are changed or replaced, the newer ones shall apply.

Article 40. Implementationresponsibility

The Drug Administration of Vietnam, the Traditional Medicine Administration and units affiliated to the Ministry of Health, Departments of Health of provinces or central-affiliated cities, Vinapharm, Vietnamese and foreign drug registrants and drug manufacturers, importers, exporters of drugs and medicinal ingredients, health facilities and facilities preparing drugs according to prescriptions are responsible for the implementation of this Circular.

Any difficulties that arising in the course of implementation of this Circular should be promptly reported to the Ministry of Health (via the Drug Administration of Vietnam or the Traditional Medicine Administration) for consideration./.

For the Minister

The Deputy Minister

Truong Quoc Cuong